WuXi Biologics Earns ISO 20400 Certification for Sustainable Procurement
WuXi Biologics has announced that it has obtained ISO 20400 Sustainable Procurement certification, a globally recognized benchmark for embedding sustainability into procurement operations while advancing accountability and transparency throughout the supply chain. This milestone underscores the company’s strong sustainability performance and reflects its ongoing commitment to building a resilient and responsible supply network.
Dr. Chris Chen, CEO of WuXi Biologics and Chair of the ESG Committee, stated: “As an active member of the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics applies internationally recognized management practices to develop a strong and reliable supply chain. This value chain not only supports long-term, sustainable business growth but also enables us to consistently deliver high-quality solutions to global clients while driving responsible development across the pharmaceutical industry.”
Comprehensive Supplier Lifecycle Management
Sustainability considerations are fully integrated into WuXi Biologics’ supplier lifecycle management framework, covering supplier screening and onboarding, risk assessment, engagement, performance evaluation, and exit processes. This end-to-end approach ensures partners uphold rigorous quality, regulatory, and sustainability standards, while enhancing supply chain visibility, reducing operational risks, improving efficiency, and encouraging responsible supplier behavior.
Advancing Net-Zero Across the Value Chain
Recognizing the urgency of addressing climate change, WuXi Biologics has implemented a holistic climate strategy supported by Science Based Targets initiative (SBTi)–aligned goals and detailed implementation roadmaps. In addition to progressing toward its own emissions targets, the company actively collaborates with suppliers through sustainable supply chain programs to generate positive environmental outcomes across the broader value chain.
As a participant in the United Nations Global Compact (UNGC), WuXi Biologics actively promotes sustainable development and has received extensive global recognition for its ESG leadership. These accolades include an MSCI AAA Rating, an EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices (DJSI), placement on CDP’s “A List” for Climate Change, Water Security, and Supplier Engagement, and the highest negligible-risk rating from Sustainalytics. The company has also been named a Sustainalytics industry and regional ESG leader for five consecutive years, included in the FTSE4Good Index Series and the Hang Seng ESG 50 Index, and rated Prime by ISS ESG.
*PSCI (Pharmaceutical Supply Chain Initiative) is a leading global association of pharmaceutical and healthcare companies dedicated to advancing excellence in safety, environmental stewardship, and social responsibility across the global healthcare value chain.
Dr. Chris Chen, CEO of WuXi Biologics and Chair of the ESG Committee, stated: “As an active member of the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics applies internationally recognized management practices to develop a strong and reliable supply chain. This value chain not only supports long-term, sustainable business growth but also enables us to consistently deliver high-quality solutions to global clients while driving responsible development across the pharmaceutical industry.”
Comprehensive Supplier Lifecycle Management
Sustainability considerations are fully integrated into WuXi Biologics’ supplier lifecycle management framework, covering supplier screening and onboarding, risk assessment, engagement, performance evaluation, and exit processes. This end-to-end approach ensures partners uphold rigorous quality, regulatory, and sustainability standards, while enhancing supply chain visibility, reducing operational risks, improving efficiency, and encouraging responsible supplier behavior.
Advancing Net-Zero Across the Value Chain
Recognizing the urgency of addressing climate change, WuXi Biologics has implemented a holistic climate strategy supported by Science Based Targets initiative (SBTi)–aligned goals and detailed implementation roadmaps. In addition to progressing toward its own emissions targets, the company actively collaborates with suppliers through sustainable supply chain programs to generate positive environmental outcomes across the broader value chain.
As a participant in the United Nations Global Compact (UNGC), WuXi Biologics actively promotes sustainable development and has received extensive global recognition for its ESG leadership. These accolades include an MSCI AAA Rating, an EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices (DJSI), placement on CDP’s “A List” for Climate Change, Water Security, and Supplier Engagement, and the highest negligible-risk rating from Sustainalytics. The company has also been named a Sustainalytics industry and regional ESG leader for five consecutive years, included in the FTSE4Good Index Series and the Hang Seng ESG 50 Index, and rated Prime by ISS ESG.
*PSCI (Pharmaceutical Supply Chain Initiative) is a leading global association of pharmaceutical and healthcare companies dedicated to advancing excellence in safety, environmental stewardship, and social responsibility across the global healthcare value chain.
Companies